CURN and KNRS Related Headlines
Go Back- Curatis Increases Revenue Growth Guidance for 2026
- Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan
- Curatis receives FDA approval to proceed with corticorelin phase 3 trial
- Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 3
- Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01
- Curatis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual Revenues
CURN and KNRS Related Press Releases
Go Back- Curatis Increases Revenue Growth Guidance for 2026
- Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan
- Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 3
- Curatis: Double-Digit Growth in Core Business and Development Milestone Achieved for C-PTBE-01
- Curatis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual Revenues
